688089.SHG Cabio Biotech Wuhan Co Ltd
- Market cap
- CNY 1.29B
- P/E
- -
- P/B
- 0.91x
- ROE
- -22.9%
- Dividend yield
- 2.79%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688089.SHG undervalued?
Graham numberThe Graham number of Cabio Biotech Wuhan Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cabio Biotech Wuhan Co Ltd fundamental analysis
No fundamental analysis for Cabio Biotech Wuhan Co Ltd yet.
Cabio Biotech Wuhan Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. The company offers polyunsaturated fatty acids, including arachidonic acid (ARA) and docosahexaenoic acid (DHA); terpenoids, such as beta (ß)-carotene and astaxanthin; and carbohydrates, such as N-acetylneuraminic acid and human milk oligosaccharides. Its products are used in human nutrition, including early…
Full company profileCabio Biotech Wuhan Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cabio Biotech Wuhan Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 190M | 229M | 286M | 312M | 323M | 351M | 433M | 444M | 556M | 575M | 120M |
| Gross Profit | 80.1M | 101M | 139M | 165M | 170M | 179M | 176M | 179M | 229M | 575M | -43.6M |
| Operating Income | 33.4M | 51.0M | 81.0M | 98.8M | 124M | 117M | 51.1M | 81.6M | 126M | 165M | -163M |
| EBITDA | 82.3M | 104M | 142M | 169M | 184M | 176M | 105M | 148M | 195M | 233M | -323M |
| Net Income | 47.0M | 65.8M | 97.0M | 118M | 131M | 129M | 64.4M | 91.4M | 124M | 157M | -319M |
| EPS | 0.37 | 0.52 | 0.77 | 0.94 | 0.78 | 0.76 | 0.38 | 0.54 | 0.74 | 0.94 | -1.92 |
| Balance Sheet | |||||||||||
| Total Assets | 477M | 506M | 581M | 1.30B | 1.38B | 1.45B | 1.61B | 1.61B | 1.69B | 1.86B | 1.62B |
| Total Liabilities | 74.2M | 42.0M | 55.0M | 48.3M | 59.3M | 66.7M | 186M | 118M | 117M | 216M | 235M |
| Shareholders' Equity | 404M | 466M | 527M | 1.25B | 1.32B | 1.38B | 1.42B | 1.48B | 1.56B | 1.63B | 1.39B |
| Cash & Short-term Investments | 44.8M | 76.0M | 122M | 844M | 861M | 676M | 527M | 240M | 153M | 278M | 137M |
| Total Debt | 40.0M | - | - | - | - | 2.42M | 33.0M | 11.7M | 18.7M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 62.5M | 101M | 106M | 132M | 146M | 103M | 176M | 68.9M | 173M | 270M | - |
| Capital Expenditure | 16.2M | 23.2M | 12.3M | 23.3M | 33.1M | 173M | 249M | 298M | 212M | 145M | 65.0M |
| Free Cash Flow | 46.3M | 77.5M | 93.8M | 109M | 113M | -70.1M | -73.1M | -229M | -38.6M | 126M | -132M |
| Ratios | |||||||||||
| ROE | 11.6% | 14.1% | 18.4% | 9.5% | 9.9% | 9.3% | 4.5% | 6.2% | 8.0% | 9.6% | -22.9% |
| ROA | 9.9% | 13.0% | 16.7% | 9.1% | 9.4% | 8.9% | 4.0% | 5.7% | 7.4% | 8.4% | -19.7% |
| Net Profit Margin | 24.7% | 28.8% | 33.9% | 37.9% | 40.4% | 36.6% | 14.9% | 20.6% | 22.4% | 27.3% | -265.0% |
| Debt to Equity | 0.10x | - | - | - | - | 0.00x | 0.02x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cabio Biotech Wuhan Co Ltd dividends
- Dividend yield
- 2.79%
- Forward dividend
- -
- Payout ratio
- 22.9%
- Ex-dividend date
- Jul 10, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 35.9M | 0.22 | 22.9% |
| 2024 | CNY 34.0M | 0.20 | 27.4% |
| 2023 | CNY 36.1M | 0.21 | 39.5% |
| 2022 | CNY 39.6M | 0.23 | 61.5% |
| 2021 | CNY 39.6M | 0.24 | 30.8% |
| 2020 | CNY 60.0M | 0.36 | 45.9% |
| 2019 | CNY 45.0M | 0.36 | 38.1% |
| 2018 | CNY 36.0M | 0.29 | 37.1% |
| 2017 | CNY 291K | 0.00 | 0.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 18, 2023.
Who owns Cabio Biotech Wuhan Co Ltd
- Insiders 52.93%
- Institutions 2.88%
- Public & others 44.19%
- Shares outstanding 166M
- Free float 85.5M
Cabio Biotech Wuhan Co Ltd company profile
- Company name
- Cabio Biotech Wuhan Co Ltd
- Ticker
- 688089.SHG
- ISIN
- CNE100005X31
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 595
- Fiscal year end
- December
- Address
- No. 89, Gaokeyuan Third Road, Wuhan, China, 430075
- Phone
- 86 27 5018 9997
- Website
- cabio.cn
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. The company offers polyunsaturated fatty acids, including arachidonic acid (ARA) and docosahexaenoic acid (DHA); terpenoids, such as beta (ß)-carotene and astaxanthin; and carbohydrates, such as N-acetylneuraminic acid and human milk oligosaccharides. Its products are used in human nutrition, including early life nutrition and dietary supplements; animal nutrition, such as economic animal and pet nutrition; personal care and cosmetics; and synthetic biology applications. The company also engages in the production of food additives and other food products; consulting services in bioengineering, environmental protection, healthcare, and food technologies; research, development, and sale of biological feed and feed additives; food wholesale; technology development; and venture capital activities. Cabio Biotech (Wuhan) Co., Ltd. was founded in 1999 and is based in Wuhan, the People's Republic of China.
Cabio Biotech Wuhan Co Ltd management
7- Mr. Dewei YiChairman & GM · born 1965
- Mr. Huabiao WangCFO & Director · born 1965
- Mr. Huarong YiEmployee Director, Deputy GM & Secretary of the Board of Directors · born 1976
- Mr. Anfeng GengDeputy General Manager · born 1976
- Mr. Xiangyu LiDeputy General Manager · born 1978
- Mr. Zhi Bo LiDeputy General Manager · born 1973
- Hao XiongHead of Accounting Department